Page 118 - TD-3-3

Tumor Discovery E-cadherin and p53 in AEL

2022;12(11):147. Genet. 2019;51:694-704.
doi: 10.1038/s41408-022-00746-x doi: 10.1038/s41588-019-0375-1
4. Ohgami RS, Chisholm KM, Ma L, Arber DA. E-cadherin is 9. Strouboulis J. Erythroleukemia: All roads lead to GATA1?
a specific marker for erythroid differentiation and has utility, Blood. 2020;136(6):648-649.
in combination with CD117 and CD34, for enumerating doi: 10.1182/blood.2020006107
myeloblasts in hematopoietic neoplasms. Am J Clin Pathol.
2014;141(5):656-664. 10. Kallakury BV, Figge J, Ross JS, Fisher HA, Figge HL,
Jennings TA. Association of p53 immunoreactivity with
doi: 10.1309/AJCP8M4QQTAZPGRP
high Gleason tumor grade in prostatic adenocarcinoma.
5. Tamura A, Uemura S, Saito A, et al. Congenital immature Hum Pathol. 1994;25(1):92-97.
pure erythroid leukemia with E-cadherin expression. Int J doi: 10.1016/0046-8177(94)90177-5
Hematol. 2017;106(5):711-717.
11. Limani R, Lež C, Krušlin B. Exploring the relationship
doi: 10.1007/s12185-017-2248-7
between E-cadherin and β-catenin cell adhesion proteins and
6. Caldwell I, Ruskova A, Royle G, Liang J, Bain BJ. Pure periacinar retraction clefting in prostatic adenocarcinoma.
erythroid leukemia: The value of E-cadherin in making the Diagnostics (Basel). 2024;14(5):511.
diagnosis. Am J Hematol. 2019;94(6):726-727.
doi: 10.3390/diagnostics14050511
doi: 10.1002/ajh.25437
12. Domingo-Claros A, Larriba I, Rozman M, et al. Acute
7. Jakobiec FA, Wolkow N, Zakka FR, Rubin PAD. Myeloid erythroid neoplastic proliferations. A biological study based
sarcoma with megakaryoblastic differentiation arising in the on 62 patients. Haematologica. 2002;87(2):148-153.
conjunctiva. Ocul Oncol Pathol. 2019;5(1):28-35.
13. Takeda J. Molecular pathogenesis and therapeutic
doi: 10.1159/000488057 targets in acute erythroid leukemia. Rinsho Ketsueki.
2022;63(2):121-133. [Article in Japanese]
8. Iacobucci I, Wen J, Meggendorfer M, et al. Genomic subtyping
and therapeutic targeting of acute erythroleukemia. Nat doi: 10.11406/rinketsu.63.121

Volume 3 Issue 3 (2024) 4 doi: 10.36922/td.3275